title: Amiodarone and the thyroid: a 2012 update.
abstract: Amiodarone-induced thyroid dysfunction occurs in 15-20% of amiodarone-treated patients. Amiodarone-induced hypothyroidism (AIH) does not pose relevant problems, is easily controlled by L-thyroxine replacement, and does not require amiodarone withdrawal. Most frequently AIH develops in patients with chronic autoimmune thyroiditis. Amiodarone- induced thyrotoxicosis (AIT) is most frequently due to destructive thyroiditis (type 2 AIT) causing discharge of thyroid hormones from the damaged, but otherwise substantially normal gland. Less frequently AIT is a form of hyperthyroidism (type 1 AIT) caused by the iodine load in a diseased gland (nodular goiter, Graves' disease). A clearcut differentiation between the two main forms is not always possible, despite recent diagnostic advances. As a matter of fact, mixed or indefinite forms do exist, contributed to by both thyroid damage and increased thyroid hormone synthesis. Treatment of type 1 (and mixed forms) AIT is based on the use of thionamides, a short course of potassium perchlorate and, if treatment is not rapidly effective, oral glucocorticoids. Glucocorticoids are the first-line treatment for type 2 AIT. Amiodarone should be discontinued, if feasible from a cardiac standpoint. Continuation of amiodarone has recently been associated with a delayed restoration of euthyroidism and a higher chance of recurrence after glucocorticoid withdrawal. Whether amiodarone treatment can be safely reinstituted after restoration of euthyroidism is still unknown. In rare cases of AIT resistance to standard treatments, or when a rapid restoration of euthyroidism is advisable, total thyroidectomy represents a valid alternative. Radioiodine treatment is usually not feasible due to the low thyroidal iodine uptake.
authors.affiliation: Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. fbogazzi@hotmail.com
authors.forename: F
authors.initials: F
authors.lastname: Bogazzi
authors.forename: L
authors.initials: L
authors.lastname: Tomisti
authors.forename: L
authors.initials: L
authors.lastname: Bartalena
authors.forename: F
authors.initials: F
authors.lastname: Aghini-Lombardi
authors.forename: E
authors.initials: E
authors.lastname: Martino
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D001281:Atrial Fibrillation / Q000188:drug therapy*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced* / Q000188:drug therapy; D013974:Thyroxine / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone; D013974:Thyroxine